Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Drug Recalls For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… NIMOTOP (nimodipine) Capsules,30 mg, Bayer Pharmaceutical Division NDA 18-869/S10 8/22/00 8/23/00 8/23/00 NIMOTOP (nimodipine) Capsules,Rx Bayer Pharmaceutical Division NDA 18-869 8/22/00 Nimotop Indications: for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranialberry aneurysms regardless of their post-ictus neurologic condition. | Nimotop (Nimodipine) capsules, Bayer Pharma, Labeling Revision | Nimodipine Capsules, Sun Pharma, Approval | Nimodipine Capsules, Barr Labs, Approval | Nimodipine Capsules, Banner Pharmacaps, Approval ^ FDA's latest approval appears at the bottom of this list. ^   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2008 Betterchem.com